Sarepta Therapeutics,, Inc. - SRPT STOCK NEWS

Sarepta Therapeutics (NASDAQ:SRPT) announced plans to initiate Part B of the MOMENTUM study for SRP-5051, potentially a pivotal trial following positive FDA interactions. This study aims to treat Duchenne muscular dystrophy and will enroll 20-40 patients aged 7 to 21, including both ambulatory and non-ambulatory individuals. Initial results from Part A show SRP-5051's efficacy, boasting significantly higher dystrophin production compared to existing treatments. The protocol for Part B will emphasize safety with magnesium supplementation due to previously noted reversible hypomagnesemia.

Sarepta Therapeutics (NASDAQ:SRPT) will present at the World Muscle Society 2021 Virtual Congress from Sept. 20-24, showcasing its commitment to developing precision genetic medicine for rare diseases. The presentations will cover important data from the company’s gene therapy and RNA platforms and address the prevalence of pre-existing antibodies to the AAVrh74 vector. All presentations will be available on-demand starting Sept. 20, 2021. Sarepta currently leads in therapies for Duchenne muscular dystrophy and has over 40 programs in various development stages.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine, announced participation in two upcoming virtual investor conferences. The events include the Morgan Stanley Global Healthcare Conference on Sept. 13, 2021, at 1:15 p.m. E.T., and the Cantor Fitzgerald Virtual Global Healthcare Conference on Sept. 27, 2021, at 1:20 p.m. E.T. Live webcasts will be available on Sarepta's website, and the presentations will be archived for 90 days. The company is committed to developing therapies for rare diseases, focusing on Duchenne muscular dystrophy and limb-girdle muscular dystrophies.

Sarepta Therapeutics (NASDAQ:SRPT) announced the recipients of Route 79, The Duchenne Scholarship Program, on World Duchenne Awareness Day. Fifteen individuals living with Duchenne muscular dystrophy will each receive scholarships of up to $5,000 to support their post-secondary education. The selection was made by an independent committee based on community involvement and personal essays. This program aims to support students with Duchenne in their educational pursuits, reflecting Sarepta's commitment to the Duchenne community.

Sarepta Therapeutics (NASDAQ:SRPT) announced on August 31, 2021, the granting of equity awards to 11 new hires as an employment inducement. The awards consisted of options to purchase 10,600 shares and 5,400 restricted stock units (RSUs). The options have an exercise price of $78.12 per share, matching the closing price on the Grant Date. Vesting for the options and RSUs occurs over four years, subject to continued employment. This initiative aligns with Nasdaq rules and reflects the company’s commitment to attracting talent in the rare disease sector.

Sarepta Therapeutics (NASDAQ:SRPT) reported second-quarter 2021 net product sales of $141.8 million, a 27% increase year-over-year. The company raised its full-year revenue guidance by nearly $30 million to between $565 million and $575 million. Following a successful end-of-phase-2 meeting with the FDA, Sarepta plans to initiate its pivotal trial for SRP-9001 in September 2021. The company also executed a licensing agreement for a gene therapy program targeting limb-girdle muscular dystrophy type 2A, underscoring its ongoing commitment to advancing genetic medicine.

Sarepta Therapeutics (NASDAQ:SRPT) has secured an exclusive license for a gene therapy candidate, CAPN-3, aimed at treating Limb-girdle muscular dystrophy type 2A (LGMD2A). This type is the most prevalent LGMD, comprising nearly a third of cases. The CAPN-3 program follows promising preclinical studies conducted by Nationwide Children's Hospital, demonstrating early proof of concept. Sarepta's gene therapy portfolio is robust, addressing six LGMD subtypes, which together account for over 70% of known LGMDs. The AAVrh74 vector used in these therapies can effectively deliver treatments to key muscle groups.

Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to 10 new employees as a part of their employment incentives on July 30, 2021. These awards include options to purchase 20,450 shares and 10,400 restricted stock units (RSUs), approved under the 2014 Employment Commencement Incentive Plan and Nasdaq Rule 5635(c)(4). The options have an exercise price of $67.78 per share, and the vesting schedule spans four years. Sarepta continues to lead in precision genetic medicine for rare diseases, with over 40 programs in development.

Sarepta Therapeutics (NASDAQ:SRPT) will announce its second quarter 2021 financial results after market close on August 4, 2021. A conference call is scheduled for 4:30 p.m. E.T. to discuss these results and provide a corporate update. Investors can access the call via phone or through the company's website, which will also archive the event for 90 days. Sarepta is focused on developing precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy, with a robust pipeline of over 40 programs.